Hodgkin lymphoma: Protecting the victims of our success

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4456-4457

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; EDITORIAL; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL;

BONE MARROW; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE;

EID: 84871814323     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.5402     Document Type: Editorial

References (14)

1. Lovecraft HP: Pickman's model. Weird Tales 10:505-514, 1927
2. DeVita VT Jr, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587-595, 1980
3. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
4. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
5. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
6. Campbell BA, Voss N, Pickles T, et al: Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size. J Clin Oncol 26:5170-5174, 2008
7. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
8. Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854, 2011
9. Carr R, Barrington SF, Madan B, et al: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340-3346, 1998
10. Moog F, Bangerter M, Kotzerke J, et al: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603-609, 1998
11. Pakos EE, Fotopoulos AD, Ioannidis JP: 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 46:958-963, 2005
12. Moulin-Romsee G, Hindié E, Cuenca X, et al: (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37:1095-1105, 2010
13. Sehn LH, Scott DW, Chhanabhai M, et al: Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29:1452-1457, 2011
14. El-Galaly TC, d'Amore F, Mylam KJ, et al: Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508-4514, 2012